trial

Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness

NCTId NCT06376734

as of 2026-07-01

Add to landscape Monitor this Ask about this

at a glance

Phase 2 · Recruiting

Enrollment 180 (estimated)

Sponsored by Brigham and Women's Hospital

Primary completion 2029-06-01

Synthesized from structured facts only — each point cited above.

Design & status

Phase

Phase 2

Status

Recruiting

Enrollment

180 (estimated)

Study type

Interventional

Allocation

Randomized

Model

Crossover

Masking

None

Start

2025-01-30

Primary completion

2029-06-01

Eligibility

ALL · 18 Years · 65 Years

Interventions & indications

Drugs

Transcranial Magnetic Stimulation

Indications

Major Depressive Disorder Generalized Anxiety Disorder Mental Disorder Generalized Anxiety Disorder Depression, Anxiety Depressive Disorder, Major Obsessive-Compulsive Disorder Schizophrenia Mood Disorders Schizophrenia Psychiatric Disorder Obsessive-Compulsive Disorder

Investigators

Shan H Siddiqi, MDPrincipal Investigator

Sites

2 total

Sunnyvale, United StatesBoston, United States

Linked catalysts

Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illn — primary completion2029-06-01

Facts & assertions

4 sourced

Enrollment

180

Phase

PHASE2

Primary Completion Date

2029-06-01

Status

RECRUITING

relationships

The graph out of here

drug

Transcranial Magnetic Stimulation

drug

lead_sponsor

Brigham and Women's Hospital

company

collaborator

National Institute of Mental Health (NIMH)

company

indication

Major Depressive Disorder

indication

Generalized Anxiety Disorder

indication

Mental Disorder

indication

investigator

Shan H Siddiqi, MD

person